Myriad Genetics (MYGN) COO receives RSU grant, shares withheld for tax

Rhea-AI Filing Summary

Myriad Genetics’ Chief Operating Officer Mark Verratti reported routine equity compensation activity. On March 12, 2026, he acquired 247,423 time-based restricted stock units, each representing one future share that vests in three equal annual installments starting one year after the grant.

On March 13–15, 2026, a total of 29,289 shares of common stock were withheld at $4.66 per share to cover tax obligations tied to the vesting of previously granted time-based and performance-based restricted stock units. After these transactions, Verratti directly held 632,770 shares of Myriad Genetics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Verratti Mark

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		A		247,423(1)	A	$0	662,059	D
Common Stock	03/13/2026		F		9,164(2)	D	$4.66	652,895	D
Common Stock	03/14/2026		F		5,418(2)	D	$4.66	647,477	D
Common Stock	03/15/2026		F		5,611(2)	D	$4.66	641,866	D
Common Stock	03/15/2026		F		9,096(3)	D	$4.66	632,770	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of time-based restricted stock units granted pursuant to the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.

2. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026.

3. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of the Issuer's Common Stock on March 13, 2026.

Remarks:

	By: Justin Hunter For: Mark Verratti	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did MYGN COO Mark Verratti report on this Form 4?

Mark Verratti reported a grant of 247,423 time-based restricted stock units and several tax-withholding dispositions totaling 29,289 shares tied to vesting of earlier awards. These are compensation-related events rather than open-market purchases or sales.

How many Myriad Genetics (MYGN) shares does the COO hold after these transactions?

Following the reported grant and tax-withholding dispositions, Chief Operating Officer Mark Verratti directly holds 632,770 shares of Myriad Genetics common stock. This figure reflects his updated ownership after the March 12–15, 2026 equity compensation and withholding activity.

What is the nature of the 247,423-share award reported by MYGN’s COO?

The 247,423-share award consists of time-based restricted stock units granted under Myriad’s 2017 equity incentive plan. Each unit represents a contingent right to receive one share and vests in three equal annual installments beginning on the first anniversary of the grant date.

Were the MYGN COO’s Form 4 transactions open-market stock sales?

No, the dispositions were not open-market sales. They represent shares of common stock withheld by Myriad Genetics to satisfy tax withholding obligations when previously granted time-based and performance-based restricted stock units vested, with values based on the March 13, 2026 closing price.

At what price were MYGN shares valued for the tax-withholding on the COO’s awards?

The shares withheld for tax obligations were valued at $4.66 per share, based on the closing price of Myriad Genetics common stock on March 13, 2026. This price was used to determine the number of shares required to cover withholding taxes.